We have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Our initial focus in stem cell therapeutics is to achieve a leadership position in:

• a. the development of identification biomarkers (a biomarker is a substance used as an indicator of a biological state relating to the complete range of genes found in biological structure and processes of the living body), that can aid in understanding the prediction, cause, diagnosis, progression, regression, or outcome of treatment of disease;
• b. the development of stem cell therapies for disease and injury; and
• c. the performance of reproductive cell/tissue laboratory services.

We have developed a patent-pending container device for cryopreservation of stem cells (the process where cells are preserved by cooling to low sub-zero temperatures) that we believe will provide significant improvements in viable cell recovery and contaminant protection.
We have developed a medium and scaffolding whose components are based on umbilical cord blood. They enhance the rate of growth of a stem cell colony. These technologies must be subject to FDA trials before production and sale.
In addition, our wholly-owned subsidiary, Proteoderm, has designed and is producing and marketing, anti-aging cosmeceuticals and cosmetics derived from stem cell products which contain a patent pending secreted matrix as an active ingredient. Proteoderm has developed an anti-aging kit under the brand name “Matrix NC-138.”

We recognize the impact on society that the scarcity of transplant grade umbilical cord blood stem cells imposes; unmet transplantation increases morbidity and mortality. Your company intends to capitalize on this need by creating new stem cell expansion and cryopreservation techniques. research publication.

Your company continues to apply its core assets in the field of diabetes and other disease entities. We are currently in negotiations to joint venture our patents and intellectual properties with other biotech companies and university centers.